The axial spondyloarthritis market is experiencing robust growth due to increasing awareness and advancements in treatment options. Rising prevalence rates and a growing focus on personalized medicine are driving market expansion, with innovative therapies and improved diagnostics contributing to a more favorable outlook. LAS VEGAS , Sept.
18, 2024 /PRNewswire/ -- Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and sacroiliac joints, which link the spine to the pelvis. It can also impact other joints and is a systemic condition, potentially affecting various body parts and organs. The condition tends to run in families and is divided into two types: ankylosing spondylitis, or radiographic axSpA, where damage to the sacroiliac joints and spine is visible on X-rays, and non-radiographic axSpA, where damage might not be seen on X-rays but can be identified using MRI.
Typically, it starts between the ages of 20 and 40, is more frequent in men, though non-radiographic axSpA can affect both genders equally. According to DelveInsight's estimates, the total prevalent population of axial spondyloarthritis was 4.5 million in 2023 in the 7MM, and these cases are expected to significantly increase during the study period (2020–2034).
As per estimates, the total diagnosed population of non-radiographic axial spondyloarthritis in the US was around 569K cases in 2023. Axial Spondyloarthritis doesn't have a cure, but treatm.